Carcinoembryonic antigen (CEA) is a useful marker to monitor patients, to evaluate tumour staging in patients with gastric cancer (Tamada et al., 1982 (Tamada et al., , 1985 Kano et al., 1987) and to predict prognosis (Maehara et al., 1990) . Ten to twenty percent of CEA-positive Japanese patients had gastric cancer Shimizu et al., 1987) . The combination of two different tumour markers is more helpful in diagnosis than a single determination. Quentmeier et al. (1987) reported the usefulness of the simultaneous measurement of carbohydrate antigen 12-5 (CA12-5), CEA and carbohydrate antigen 19-9 (CA19-9) for gastric cancer and colon cancer patients. They stated that simultaneous determination of the three markers led to a more precise assessment of the outcome for these patients, that is 17.1% (CEA alone) to 34.5% (three determinations) (Quentmeier et al., 1987) .
We have now used serum sialyl-Tn antigen (STN) in combination with CEA for assay. STN is an abnormal glycoprotein, detected using monoclonal antibody TKH-2 (Kjeldsen et al., 1988) and specific to cancer tissue. STN is expressed in colon cancer cells but not in normal colon cells (Itzkowitz et al., 1989) . In gastric cancer tissue, STN is expressed specifically in malignant cells (Maeda et al., 1992; Yamada et al., 1992) . In previous work, we examined preoperative serum STN levels in gastric cancer patients and its value as a tumour marker for gastric cancer was apparent. Patients with high serum STN levels have more advanced gastric cancer and their prognosis is poorer than patients with lower STN levels (Takahashi et al., 1993) .
In the present work, we examined the usefulness of the combined assay of CEA and STN in patients with gastric cancer. Serum STN levels were measured using a one-step radioimmunoassay kit (S-Tn Otsuka; Otsuka Assay Laboratories, Tokushima, Japan) (Imura et al., 1989) . This kit employs competitive binding to the radiolabelled monoclonal antibody TKH-2 between serum STN and STN-coated beads (an immunoradiometric competitive inhibition assay) (Kjeldsen et al., 1988) . Venous blood samples were immediately separated by centrifugation and placed in liquid nitrogen. The cut-off value between normal and elevated STN titres was set to 45 U ml-'. This cut-off value, 45 U ml-1, is the mean plus one standard deviation of findings in normal volunteers (Imura et al., 1989) . Serum CEA levels were determined by the double-antibody method (Maehara et al., 1990) . Differentiation between normal and elevated CEA titres was based on 5.0 ng ml-' as the uppermost normal concentration. We classified the patients into four groups according to these cut-off values: (A) low CEA and low STN levels [CEA (-) STN ( Clinicopathological data were stored in an IBM (Armonk, NY, USA) 4381 mainframe computer. The Biomedical Computer Program (BMDP Statistical Package Program, Los Angeles, CA, USA) was used for all statistical analyses (Dixon, 1988) . Data were analysed using the chi-square and Mann-Whitney U-tests. For these analyses, the BMDP P4F and P3f programs were used. Survival curves were calculated by the Kaplan-Meier method, using the BMDP PIL program. Comparisons among the four groups were made using the generalised Wilcoxon test to analyse equality of the survival curves. A P-value of less than 0.05 was considered to be Correspondence: Y. Maehara. Received 15 January 1993; and in revised form 23 July 1993. statistically significant. In the statistical analysis, deaths due to causes other than gastric carcinoma were considered censored cases. Unknown data were also excluded from statistical analysis.
Patients and methods

From
Results
Positive rate of both CEA and STN, and correlation of these markers The positive rate of these parameters in case of CEA assay alone was 9.2% (32/349), while that of STN alone was 13.2% (46/349). The positive rate for patients either CEA (+) or STN (+) was 18.1% (63/349). Figure 1 shows the distribution of CEA and STN levels of 349 patients; there was no correlation between the two markers (r = 0.023).
Clinicopathological factors
The clinicopathological data on the 349 patients are given in Table I 
Survival rates
No patient was lost to follow-up. The mean follow-up time ± s.d. at the time of analysis (November 1991) was 6.07 ± 0.92 years for the 208 survivors of the total 349 patients. The post-operative survival curve among the groups was also compared (Figure 2) . The 5-year survival for patients with CEA (+) STN (+) (group D) was 14.5 ± 9.5%, while that of patients in other groups was 44.1 ± 12.7% for the CEA (+) STN (-) group (group C) (P <0.05), 60.1 ± 9.5% for the CEA (-) STN (+) group (group B) (P<0.05) and 77.6 ± 9.5% for the CEA (-) STN (-) group (group A) (P<0.05). 
Discussion
Changes in surface membrane glycoproteins are common phenomena in cancer cells (Springer, 1984) . Itzkowitz et al. (1989 Itzkowitz et al. ( , 1990 reported that the rate of expression of STN is low in normal colon mucosa, and that expression of STN is an independent prognostic factor for colon cancer patients. STN is little expressed in the normal stomach mucosa, yet it is expressed in 47.8-54.1% of cancer cells (Maeda et al., 1992; Yamada et al., 1992) . Thus, STN is specifically related to a cancer state and the serum STN level is considered to be closely related to a progressive state of the cancer. We have noted that gastric cancer patients with high preoperative STN levels tend to have an advanced malignant lesion and that the prognosis of this group is less satisfactory than that of the low-STN group (Takahashi et al., 1993) . CEA is also a useful marker for monitoring patients with gastrointestinal malignancies, and to predict recurrences (Tamada et al., 1982 (Tamada et al., , 1985 Kano et al., 1987; Maehara et al., 1990) . Prevalence of CEA positivity increases as the disease progresses (Shimizu et al., 1987) . However, biochemically and immunologically, there is a substantial difference between CEA and STN. CEA is a high molecular weight glycoprotein with the immunodeterminant located on the protein portion of the molecule (Gold et al., 1965) , whereas STN is a highly glycosylated, mucin-like glycoprotein circulating in the serum of cancer patients, and the immunodeterminant is a sialylated form of glycoprotein containing N-acetylgalactose connected by O-glycosidic linkages to serine or threonine residues in the protein backbone (Kjeldsen et al., 1988) . The immunodeterminant of the former is a protein antigen that is directly encoded by a specific antigen, whereas that of the latter is the carbohydrate side chain of the molecule, which is synthesised by gene-encoded glycosyltransferase enzyme, which adds sugars in a sequential manner (Itzkowitz & Kim, 1986; Kjeldsen et al., 1988) . As shown in Figure 1 , the distribution of these two markers is not correlated, thus there may be some difference between tumours in patients with high CEA levels and those with high STN levels. Accordingly we separated our patients into four groups -CEA (+) STN (+) (group D), CEA (-) STN (+) (group B), CEA (+) STN (-) (group C) and CEA (-) STN (-) (group A) -so as to obtain a more precise assessment of the prognosis.
As residual or occult tumour cells in gastric cancer may grow rapidly in the post-operative period, any delay in ingestion of anti-cancer drugs reduces the potential for controlling residual tumours (Schabel, 1975; Gunduz et al., 1979 RO, gastric resection, including the incomplete removal of group I nodes; RI, gastric resection, including the complete removal of group I lymph nodes; R2, gastric resection, including the complete removal of groups 1 and 2 lymph nodes; R3, gastric resection, including the complete removal of groups 1, 2 and 3 lymph nodes. NS, not significant. metastasis, serosal invasion, lymph node metastasis and peritoneal dissemination, and found evidence for independent prognostic factors in gastric cancer patients (Maehara et al., 1991a,b) . Whilst these factors can be defined at the time of surgery, CEA and STN levels can be determined simply and rapidly prior to the operation. We conclude that the combined CEA and STN assay is useful for determining the outcome in patients with gastric cancer. Intensive chemotherapy and close follow-up are recommended for such patients.
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